Targeted Delivery of Dendritic Polyglycerol–Doxorubicin Conjugates by scFv-SNAP Fusion Protein Suppresses EGFR+ Cancer Cell Growth
Citations Over TimeTop 10% of 2013 papers
Abstract
Development of effective polymer-based nanocarriers for the successful application in cancer therapy still remains a great challenge in current research. In the present study we present a dendritic polyglycerol-based multifunctional drug immunoconjugate that specifically targets and kills cancer cell lines expressing epidermal growth factor receptor (EGFR). The nanocarrier was provided with a dendritic core as a multifunctional anchoring point, doxorubicin (Doxo) coupled through a pH-sensitive linker, a fluorescence marker, poly(ethylene glycol), as solubilizing and shielding moiety, and a scFv antibody conjugated through the SNAP-Tag technology. The study provides the proof of principle that SNAP-tag technology can be used to generate drug-carrying nanoparticles efficiently modified with single-chain antibodies to specifically target and destroy cancer cells.
Related Papers
- → Delivery of Doxorubicin Using Double-Layered Core–Shell Nanocarrier Based on Magnetic Fe3O4 Core and Salep Shells(2018)20 cited
- → The emergence of nanocarriers in the management of diseases and disorders(2023)5 cited
- → General justification in terms of effectiveness and toxicities for the use of nanocarriers(2023)3 cited
- → Selective killing of carcinoembryonic-antigen (CEA)-producing cells in vitro by the immunoconjugate cytorhodin-S and CEA-reactive cytorhodin-S antibody CA208(1989)9 cited
- [Application of monoclonal antibody for cancer therapy].(1994)